How do sermorelin and ipamorelin trigger GH through different receptors?
The pituitary gland releases growth hormone in response to two primary upstream signals: growth hormone-releasing hormone (GHRH), produced by the hypothalamus, and ghrelin, produced primarily in the stomach. These signals bind to different pituitary receptors — the GHRH receptor and the growth hormone secretagogue receptor (GHSR, also called the ghrelin receptor). Sermorelin targets the first system. Ipamorelin targets the second.
Sermorelin acetate is a 29-amino-acidsynthetic analogue of the first 29 amino acids of endogenous GHRH. It binds the pituitary GHRH receptor and triggers GH pulse release through the same mechanism the hypothalamus uses naturally. Because it operates within the physiological GHRH signaling axis, the pituitary’s normal GH feedback loop — regulated by somatostatin — remains intact.
Ipamorelin is a pentapeptide ghrelin-mimetic that binds the GHSR. It was developed specifically to isolate GH-releasing activity from the broader effects of older ghrelin-mimetics like GHRP-6, which also elevated cortisol, prolactin, and ACTH. Animal studies published in 1998 demonstrated ipamorelin’s selectivity advantage: it stimulated GH release with minimal off-target hormone effects at therapeutic dose ranges.
Sermorelin vs ipamorelin: key differences at a glance
| Factor | Sermorelin | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor (pituitary) | GHSR / ghrelin receptor |
| Peptide type | 29-amino-acid GHRH analogue | Pentapeptide ghrelin-mimetic |
| FDA history | Formerly FDA-approved (Geref, pediatric GHD) | No FDA approval; PEND status |
| US compounding status | Category 1 — legally available via 503A Rx | PEND — cannot be legally compounded now |
| Human clinical data | Extensive (multiple published human trials) | Primarily preclinical; limited human data |
| GH selectivity | High (GHRH-axis specific) | High (minimal cortisol/prolactin vs older GHRPs) |
| Somatostatin feedback | Intact — natural pulsatility preserved | Intact — works additively with GHRH axis |
Mechanism differences: GHRH axis vs ghrelin axis
Understanding the mechanistic difference matters for two reasons: pulse quality and regulatory classification.
GHRH-axis peptides (sermorelin, CJC-1295) stimulate GH secretion by activating the receptor that natural GHRH uses. GH release is pulsatile because somatostatin periodically inhibits the axis — sermorelin works within that rhythm rather than overriding it. The GH pulses produced are physiologically timed and somatostatin-limited.
Ghrelin-axis peptides (ipamorelin, GHRP-6, GHRP-2) activate GHSR. The GHSR-mediated pathway can augment GH pulse amplitude in combination with GHRH-axis stimulation — which is why clinicians interested in maximizing GH pulse amplitude have historically stacked a GHRH analogue with a ghrelin-mimetic. The two receptor systems are additive rather than redundant. Ipamorelin is considered the most selective GHSR agonist in this class because it minimizes cortisol and prolactin side effects relative to older GHRPs.
What both systems share: neither supplies exogenous growth hormone. Both work upstream of the pituitary to stimulate the gland’s own production, preserving the physiological regulation that exogenous HGH bypasses.
Both peptides stimulate the body’s own growth hormone, but only sermorelin is a Category 1 substance that US compounding pharmacies can legally prepare today.
Evidence base: where sermorelin and ipamorelin differ
Sermorelin has the more mature human evidence base. It received FDA approval for pediatric growth hormone deficiency assessment and treatment under the brand name Geref. Studies in adults with growth hormone insufficiency demonstrated that sermorelin administration can increase GH and IGF-1 levels, with associated improvements in body composition markers observed in some populations. Published clinical data from human trials exists across multiple research groups, which strengthens the reproducibility argument.
Ipamorelin’s published evidence base is primarily preclinical. The foundational 1998 selectivity study demonstrated ipamorelin’s GH-releasing specificity in animal models. Subsequent animal studies explored its effects on bone density, body composition, and GH pulse characteristics. Human clinical trial data is substantially more limited than for sermorelin, and ipamorelin has not received FDA approval for any indication.
This evidence asymmetry is a material consideration. Sermorelin’s mechanism and effects are better characterized in humans. Ipamorelin’s proposed benefits in humans — while biologically plausible from the preclinical data — rest on an evidence ladder that has fewer human rungs.
Is sermorelin or ipamorelin legally available in the US today?
This is where the comparison becomes practically consequential for anyone considering a supervised peptide protocol.
Sermorelin is a Category 1 bulk drug substance under FDA compounding regulations. That designation means licensed 503A compounding pharmacies in the United States can legally prepare and dispense it when prescribed by a licensed clinician. A patient who receives a sermorelin prescription from a telehealth or in-person clinician can have that prescription filled by a licensed US pharmacy and receive a compounded product with traceable sourcing, sterility testing, and known potency. No hidden overseas supply chain.
Ipamorelin does not currently hold a Category 1 classification. Its regulatory status is pending — it has not been placed on the list of substances licensed compounding pharmacies may use. As of this writing, licensed US compounding pharmacies cannot legally prepare or dispense ipamorelin. Products sold through online vendors or gray-market sources as “research chemicals” carry significant risks: unverified purity, unknown sterility, inaccurate dosing, and no regulatory accountability.
CJC-1295 (the other commonly paired GHRH analogue) shares ipamorelin’s pending regulatory status — neither is currently available through legitimate US compounding pathways.
Which peptide should you choose for a GH support protocol today?
If you are researching growth hormone peptides because you want a legitimate, physician-supervised protocol available right now, the practical answer is sermorelin. It is legally available through licensed 503A compounding pharmacies with a clinician’s prescription. A knowledgeable clinician can evaluate your GH/IGF-1 baseline, review your health history, prescribe an individualized sermorelin protocol, and monitor your response over time.
The CJC-1295 + ipamorelin combination frequently discussed in peptide communities as the “optimal” GHSR + GHRH stack is not currently accessible through legal US compounding channels. For patients interested in dual-axis GH support, a clinician-supervised sermorelin protocol represents the legally and clinically sound starting point.
Regulatory classifications can change as the FDA continues its bulk substance review process. Ipamorelin’s status is listed as pending rather than prohibited, which means reclassification is possible as the review proceeds.
Side effect profiles: what the research reports
Sermorelin’s side effect profile is documented in human clinical literature. The most commonly reported adverse effects in clinical studies include injection-site reactions (redness, swelling, or pain at the subcutaneous injection site), flushing, and headache. These are generally mild and transient. Rare cases of antibody formation have been reported but clinical significance appears low in published data.
Ipamorelin’s side effect data comes predominantly from animal studies and limited human reports. In the selectivity research, ipamorelin’s specific advantage over older GHRPs was the absence of meaningful cortisol, prolactin, or ACTH elevation — a significant improvement over GHRP-6 in preclinical models. Transient headache and flushing are reported in the human experience, consistent with the GHSR-activation signature seen in this peptide class.
Neither peptide should be used without clinical evaluation. GH-stimulating peptides are contraindicated in active malignancy and carry potential considerations in diabetic patients (given IGF-1’s effect on insulin sensitivity). A clinician review is not optional for these compounds — it is necessary.
Frequently asked questions
What is the main difference between sermorelin and ipamorelin?
Sermorelin is a GHRH analogue — it activates the pituitary GHRH receptor, which is the same receptor the body's natural growth hormone-releasing hormone uses. Ipamorelin is a ghrelin-mimetic GHSR agonist that activates a separate receptor system. Both stimulate pituitary GH release, but through different pathways with different selectivity profiles.
Which peptide is more selective for growth hormone?
Ipamorelin is generally considered more selective. Animal studies show that ipamorelin stimulates GH release without meaningfully elevating cortisol, prolactin, or ACTH at therapeutic doses — a selectivity advantage over older GHRPs such as GHRP-6. Sermorelin, acting on the GHRH receptor, is also physiologically selective but through a different receptor family.
Is sermorelin or ipamorelin FDA-approved?
Sermorelin acetate received FDA approval for pediatric growth hormone deficiency diagnosis and treatment (Geref, now discontinued as a branded product). It remains a Category 1 bulk substance available through licensed 503A compounding pharmacies. Ipamorelin is currently a PEND-status peptide — not placed on the Category 1 list — and is not legally available through licensed US compounding pharmacies at this time.
Can sermorelin and ipamorelin be used together?
The combination of a GHRH analogue (sermorelin or CJC-1295) with a ghrelin-mimetic (ipamorelin) is frequently discussed in research and wellness communities because the two receptor systems are believed to have a synergistic effect on GH pulse amplitude. However, combination use requires clinician oversight, and ipamorelin's current regulatory status limits its legal availability through US compounding channels.
Which peptide is currently available through a licensed telehealth provider?
Sermorelin is the legally available option through licensed 503A compounding pharmacies in the US. Ipamorelin's regulatory status remains pending Category 1 classification, meaning licensed pharmacies cannot currently compound it. Patients interested in GH support through a legitimate clinical pathway should start with sermorelin.
Does sermorelin work the same way as growth hormone injections?
No. Sermorelin does not replace growth hormone — it stimulates the pituitary to produce its own GH in a pulsatile, physiologically regulated pattern. This is distinct from exogenous HGH injections, which supply GH directly and bypass pituitary feedback mechanisms. The pulsatile nature of sermorelin-stimulated release is considered more physiologically aligned.